Literature DB >> 17556368

The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe.

Marjon van Slegtenhorst1, Damir Khabibullin, Tiffiney R Hartman, Emmanuelle Nicolas, Warren D Kruger, Elizabeth Petri Henske.   

Abstract

Birt-Hogg-Dube (BHD) is a tumor suppressor gene disorder characterized by skin hamartomas, cystic lung disease, and renal cell carcinoma. The fact that hamartomas, lung cysts, and renal cell carcinoma can also occur in tuberous sclerosis complex (TSC) suggests that the BHD and TSC proteins may function within a common pathway. To evaluate this hypothesis, we deleted the BHD homolog in Schizosaccharomyces pombe. Expression profiling revealed that six permease and transporter genes, known to be down-regulated in Deltatsc1 and Deltatsc2, were up-regulated in Deltabhd, and levels of specific intracellular amino acids known to be low in Deltatsc1 and Deltatsc2 were elevated in Deltabhd. This "opposite" profile was unexpected, given the overlapping clinical phenotypes. The TSC1/2 proteins inhibit Rheb in mammals, and Tsc1/Tsc2 inhibit Rhb1 in S. pombe. Expression of a hypomorphic allele of rhb1(+) dramatically increased permease expression levels in Deltabhd but not in wild-type yeast. Loss of Bhd sensitized yeast to rapamycin-induced increases in permease expression levels, and rapamycin induced lethality in Deltabhd yeast expressing the hypomorphic Rhb1 allele. In S. pombe, it is known that Rhb1 binds Tor2, and Tor2 inhibition leads to up-regulation of permeases including those that are regulated by Bhd. Our data, therefore, suggest that Bhd activates Tor2. If the mammalian BHD protein, folliculin, similarly activates mammalian target of rapamycin, it will be of great interest to determine how mammalian target of rapamycin inhibition in BHD patients and mammalian target of rapamycin activation in TSC patients lead to overlapping clinical phenotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556368     DOI: 10.1074/jbc.M700857200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  The folliculin mutation database: an online database of mutations associated with Birt-Hogg-Dubé syndrome.

Authors:  Ming-Hui Wei; Patrick W Blake; Julia Shevchenko; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

3.  H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.

Authors:  Hisashi Hasumi; Yukiko Hasumi; Masaya Baba; Hafumi Nishi; Mitsuko Furuya; Cathy D Vocke; Martin Lang; Nobuko Irie; Chiharu Esumi; Maria J Merino; Takashi Kawahara; Yasuhiro Isono; Kazuhide Makiyama; Andrew C Warner; Diana C Haines; Ming-Hui Wei; Berton Zbar; Herbert Hagenau; Lionel Feigenbaum; Keiichi Kondo; Noboru Nakaigawa; Masahiro Yao; Adam R Metwalli; W Marston Linehan; Laura S Schmidt
Journal:  Hum Mol Genet       Date:  2017-01-15       Impact factor: 6.150

4.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

5.  The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1.

Authors:  Liron Bar-Peled; Lynne Chantranupong; Zhi-Yang Tsun; Roberto Zoncu; Tim Wang; Choah Kim; Eric Spooner; David M Sabatini
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

Review 6.  Multiple amino acid sensing inputs to mTORC1.

Authors:  Mitsugu Shimobayashi; Michael N Hall
Journal:  Cell Res       Date:  2015-12-11       Impact factor: 25.617

Review 7.  Pulmonary manifestations of Birt-Hogg-Dubé syndrome.

Authors:  Nishant Gupta; Kuniaki Seyama; Francis X McCormack
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

8.  The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis.

Authors:  Kriti Gaur; Jinghong Li; Dakun Wang; Pranabananda Dutta; Shian-Jang Yan; Amy Tsurumi; Hartmut Land; Guan Wu; Willis X Li
Journal:  Hum Mol Genet       Date:  2012-10-16       Impact factor: 6.150

9.  Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis.

Authors:  Michael S Nahorski; Laurence Seabra; Ania Straatman-Iwanowska; Aileen Wingenfeld; Anne Reiman; Xiaohong Lu; Jeff A Klomp; Bin T Teh; Mechthild Hatzfeld; Paul Gissen; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

10.  Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK.

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane L James; Elena N Atochina-Vasserman; Victoria Stepanova; Seung-Beom Hong; Hua Li; Linda Gonzales; Masaya Baba; W Marston Linehan; Andrew J Gow; Susan Margulies; Susan Guttentag; Laura S Schmidt; Vera P Krymskaya
Journal:  Cell Rep       Date:  2014-04-13       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.